Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma.

What Was Tested

This randomized controlled trial looks at Gonadorelin.

In this study, the researchers characterized the isotype/subclass profiles of the anti-GnRH humoral response generated by the vaccination and analyzed its association with patients' clinical outcomes.

Who Took Part

The abstract describes 34 patients taking part.

PubMed tags the participants as men only.

The immunoglobulin isotypes and IgG subclasses of the antibody responses of 34 patients included in a randomized, open, prospective phase I/II clinical trial were characterized.

Every patient included in the study had a diagnosis of locally advanced prostate adenocarcinoma at stages 3 and 4 and received immunization with the vaccine candidate.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Gonadorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Additionally, serum testosterone and prostate specific antigen (PSA) concentrations, serving as indicators of tumor response, were determined.

The type of anti-GnRH antibody response was correlated to the time elapsed until the first biochemical recurrence in patients and the outcome of the disease.

What Was Measured

Topics PubMed links to this paper include Gonadotropin-Releasing Hormone, Prostate-Specific Antigen, Prostate, Neoplasm Recurrence, Local, Immunization, Prostatic Neoplasms and Vaccination.

The authors tagged it with the keywords GnRH-based vaccine, anti-GnRH response, castration-sensitive prostate cancer, immunoglobulin isotypes and therapeutic vaccine.

What This Means in Plain Language

The paper is a randomized study of Gonadorelin in 34 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Technology in cancer research & treatment), a journal based in United States.

More context: the Gonadorelin compound page, all human trials.